To present ABA data graphs percentages and anecdotes without misleading readers, define the unit, cohort, numerator, denominator, time window, inclusion rule, missing data, comparison, uncertainty, and source. Use honest axes and labels, show counts with percentages, separate examples from representative evidence, and explain material burden or unwanted effects. Protect client privacy and communication authorship, and never let a decorative chart imply causality, typicality, precision, or benefit the data cannot support.

Define Tomas's statement unit and audience

Good data presentation makes the underlying cohort and uncertainty visible. It helps readers reason instead of nudging them toward a predetermined story. Teams asking how to present ABA data graphs percentages and anecdotes without misleading readers need the exact draft, full surrounding message, speaker, represented role, audience, channel, purpose, evidence date, permission state, disclosure, approver, and correction trigger before release.

Build Tomas's public data-display specification

Specify the question, audience, data owner, unit, eligible cohort, event dates, numerator, denominator, maturity rule, exclusions, missingness, aggregation, comparison, uncertainty, visual scale, annotation, client relevance, burden, privacy state, source version, reviewer, and approved caption. Freeze definitions before calculating. Show N/A when nothing is eligible and keep zero distinct from missing. Link anecdotes to their purpose without counting them as outcome evidence.

Protect clients and audiences in Tomas's review

Across Tomas's twenty graphs, percentages, tables, dashboards, case examples, and narrative summaries, protect client dignity, privacy, communication authorship, consent and authorization where required, disability and language access, fair representation, current credentials, evidence limits, and clear disclosures. Hold unsupported or unauthorized content instead of relying on a footnote to neutralize the main message.

Work through Tomas's fictional example

Tomas reviews 20 displays. Fourteen pass initial data, visual, privacy, and interpretation review. Three omit counts, one truncates an axis, one combines immature and mature cases, and one case example lacks a clear fictional label. Each returns for a focused correction before release. Preserve every proposed, revised, approved, released, reused, corrected, retracted, retired, held, and unresolved unit with its original version, evidence, permissions, owner, dates, channels, and validation.

Use Tomas's denominator carefully

Initial display readiness is 14 of 20, or 70%. The six corrected displays remain in the same review cohort. A graph-level pass rate says nothing about clinical outcomes shown inside the graphs.

Assign Tomas's decisions to qualified owners

Tomas's data owner defines calculations. Qualified clinical and statistical reviewers interpret meaning. Privacy and access owners review disclosure and usability. The client or data subject retains authorship of quoted communication where used with a valid route.

Address Tomas's main interpretation risk

Visual polish can hide unstable denominators, excluded cases, or a baseline that changes across panels. Make every change in unit, cohort, or scale easy to see.

Verify Tomas's public control before release

Tomas rebuilds sampled figures from source rows and gives the display to a reviewer without its intended conclusion. The reviewer states the denominator, comparison, timeframe, and message they perceive. Misunderstanding triggers a revised chart, caption, or decision to omit it.

Place Tomas's review inside organizational accountability

For Tomas's public data-display specification, the CASP Organizational Guidelines public overview provides high-level business, clinical-operations, and risk-management scope for autism service organizations. CASP sells the detailed guidelines. This article's claim controls are Finni's editorial design, not a CASP marketing rule, legal conclusion, or approval of any statement.

Apply professional-statement duties to Tomas's actual role

Tomas's speaker analysis starts with role and scope. The current BACB Ethics Code applies to BCBA and BCaBA certificants and people who completed an application and addresses public statements, intellectual property, confidentiality, competence, and accuracy. BACB has no separate organization or corporation jurisdiction, so entity, workforce, legal, and channel controls remain necessary.

Test the overall advertising message for Tomas

Tomas's advertising review uses the FTC small-business advertising FAQ, which says advertising must be truthful and nondeceptive, objective claims need a reasonable basis before dissemination, and express and implied messages matter in context. It also explains that health or safety claims generally require competent and reliable scientific evidence. Apply the actual speaker, entity, medium, claim, and jurisdiction.

Match Tomas's health claim to its evidence

The FTC Health Products Compliance Guidance is staff business guidance without the force of law and says its principles apply to marketing of health-related products. It emphasizes accurate express and implied claims, appropriate scientific support, relevant population and outcome evidence, and limits on testimonials. It creates no safe harbor for Tomas.

Handle endorsements and reviews separately for Tomas

The FTC endorsements, influencers, and reviews page points to current Endorsement Guides and the Consumer Reviews and Testimonials Rule. It highlights material-connection disclosure and genuine consumer feedback. Tomas should verify the actual rule, relationship, review practice, platform, and date rather than treating an honest opinion as substantiation.

Require prior support for Tomas's objective claim

The FTC Advertising Substantiation Policy Statement states that advertisers need a reasonable basis for objective express and implied claims before dissemination and at least the level of support they claim. Tomas's approval record should therefore exist before release; a later study, disclaimer, guarantee, or satisfied customer does not retroactively supply the missing basis.

Classify HIPAA marketing for Tomas

Tomas's HIPAA marketing review starts with entity status. HHS marketing guidance explains that marketing uses or disclosures of PHI by covered entities generally require an individual's written authorization, with defined exceptions. Determine the activity, remuneration, recipient, and purpose. A clinical consent, testimonial agreement, or public post does not automatically authorize every marketing use or downstream reuse.

Prove de-identification rather than assuming it for Tomas

For HIPAA covered entities, HHS de-identification guidance recognizes Expert Determination and Safe Harbor methods and explains that properly de-identified data retains a very small residual risk. Tomas should document the method, provenance, limitations, and other-law or contractual constraints; deleting names or combining cases is not a method by itself.

Make Tomas's released message usable

For covered title II or title III entities, DOJ effective-communication guidance explains that aids and services depend on the nature, length, complexity, context, and person's usual communication method. Apply the actual entity and rule. Tomas's claims, evidence limits, sponsorships, corrections, and privacy choices should be accessible in the format where the audience receives them.

Choose Tomas's next review trigger

Review after data refresh, late record, denominator change, source correction, privacy request, audience change, reused visual, complaint, or new evidence that alters interpretation. Record the changed fact, affected statement and audience, immediate containment, source and permission state, qualified owner, correction need, channels, and validation result.

Close Tomas's public-statement record with evidence

Review the public data-display specification with Tomas, qualified clinical and organizational leaders, the named speaker or author, affected clients or representatives as applicable, and the specialists named in the manifest. Confirm that personal, professional, organizational, educational, marketing, research, testimony, privacy, and employment routes remain distinct; every claim and disclosure is traceable; accessibility is tested; and unresolved content has an accountable endpoint. Keep this page draft and noindex until every required review is complete.

Related resources

Sources